- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02650674
Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2006
- University of Sydney
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Aged between 18-45 years.
- Non-smoker.
- BMI values: between 19-25 kg/m2 (bounds included) for Caucasian subjects and between 19-23 kg/m2 (bounds included) for Asian subjects (WHO expert consultation).
- Ethnicity: Caucasian subjects will have both parents from Caucasian ancestry. Asian subjects will have both parents from Asian country and will be born in an Asian country. Asian countries are: Brunei Darussalam, Cambodia, China, Dem. People's Republic of Korea, Hong Kong SAR (China), Indonesia, Japan, Lao People's Democratic Republic, Macao SAR (China), Malaysia, Mongolia, Myanmar, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Viet Nam.
- Sex ratio: Around half of the subjects should be male and half of the subjects should be female within each study group. A plus or minus 1 subject tolerance will be accepted.
- Healthy subjects with:
Normal glucose tolerance Normal laboratory values for various measures of metabolic health (full blood count, gamma-GT, AST, ALT, glucose, TAGs, total cholesterol, HDL-cholesterol, LDL-cholesterol); Normal systolic blood pressure (100-150 mmHg); Normal diastolic blood pressure (60-90 mmHg); Normal resting heart rate (50-90 beats per minutes after 3 minutes rest).
- Stable dietary habits; normal eating patterns; no history of eating disorders or strict dieting.
- Moderate level of physical activity (from basic daily activity to a high level of physical activity (regular physical activity at least 3 times per week))
- Able to fast for at least 10 hours the night before each test session.
- Able to refrain from eating legumes and drinking alcohol the day before each test session.
- Subject covered by social security or covered by a similar system
- Subject not taking any treatment for anorexia, weight loss, or any form of treatment likely to interfere with metabolism or dietary habits
- Subject having given written consent to take part in the study.
Exclusion Criteria:
- Following a restrictive diet.
- Family history of Diabetes Mellitus or obesity
- Suffering from any clinical, physical or mental illness.
- Suffering from any food allergies or hypersensitivities (wheat, milk, egg, nuts, etc).
- Taking any regular prescription medication at the time of inclusion (except regular oral contraception medication)
- Female who is pregnant (positive test results), lactating, planning pregnancy or not using acceptable contraceptive.
- Females who consistently suffer from premenstrual tension and marked changes in appetite during their menstrual cycle.
- Subject having taken part in another clinical trial within the last week.
- Subject currently taking part in another clinical trial or being in the exclusion period of another clinical trial.
- Subject undergoing general anaesthesia in the month prior to inclusion.
- Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Product A: NP-0148
Cereal product belVita Milk & Cereals - High in SDS
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Eksperimentel: Product B: NP-0149
Cereal product belVita Honey & Nuts - High in SDS
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Eksperimentel: Product C: NP-0150
Cereal product belVita Mixed Berry - High in SDS
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Eksperimentel: Product D: NP-0151
Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Eksperimentel: Product E: NP-0152
Cereal product Kellogg's Trésor Duo Choco - Low in SDS
|
Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
|
|
Eksperimentel: Glucose reference
Glucose solution performed on three occasions
|
Glucose solution providing 50 g of available carbohydrates in 250 ml of water.
This will be performed 3 times
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Glycaemic index values of five cereal products
Tidsramme: 2 hours after food consumption
|
Determination of GI in both Caucasian and Asian subjects
|
2 hours after food consumption
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Glycaemic response assessed by the glycemic index (GI) values of five cereal products
Tidsramme: 2 hours after food consumption
|
Determination of GI in the global population
|
2 hours after food consumption
|
|
Glycaemic response assessed by the postprandial changes in glycaemia over 2 hours (iAUC0-120) after consumption of the test products
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Glycaemic response assessed by the kinetic of glycemia over the 120 minutes
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Glycaemic response assessed by the peak value of glycemia
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Glycaemic response assessed by the delta value between baseline and peak values of glycemia
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the insulinemic index (II) values of five cereal products
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the postprandial changes in insulinemia over 2 hours (iAUC0-120) after consumption of the test products
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the kinetic of insulinemia over the 120 minutes
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the peak value of insulinemia
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulinaemic response assessed by the delta value between baseline and peak values of insulinemia
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Insulin / glucose ratio (II/GI) evaluation of five cereal products
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Postprandial changes in insulin / glucose over 2 hours (iAUC0-120) after consumption of the test products
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Kinetic of insulin / glucose over the 120 minutes
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Peak value of insulin / glucose ratio
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
|
Delta peak value between baseline and peak values of insulin / glucose ratio
Tidsramme: 2 hours after food consumption
|
This parameter will be analyzed first in both Caucasian and Asian populations and second globally
|
2 hours after food consumption
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Jennie Brand Miller, University of Sydney
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- KBE043
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Metabolisk lidelse
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbejdspartnereIkke rekrutterer endnuLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitis | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpanien
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisKina
-
Southern California Institute for Research and...Ikke rekrutterer endnuMASH - Metabolic Dysfunction-Associated Steatohepatitis
-
Nabiqasim Industries (Pvt) LtdRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisPakistan
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
Tangram Therapeutics PlcRekrutteringSunde deltagere | MASH - Metabolic Dysfunction-Associated SteatohepatitisDet Forenede Kongerige
-
University of Campania Luigi VanvitelliAfsluttetMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
University of Campania Luigi VanvitelliAfsluttetKardiovaskulære begivenheder | MASLD | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
Kliniske forsøg med Product A: NP-0148
-
Vaccitech (UK) LimitedAfsluttet
-
RenJi HospitalAfsluttetHepatocellulært karcinom | Leverkræft | Resistent kræftKina
-
Cancer Insight, LLCBristol-Myers Squibb; Cancer Research Institute, New York City; Akamis BioAfsluttetMetastatisk bugspytkirteladenokarcinomForenede Stater
-
Altria Client Services LLCICON Clinical ResearchAfsluttetBrug af tobak | TobaksrygningForenede Stater